Networks of Innovation: Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995 (Hardcover)

by Louis Galambos (Author), Jane Eliot Sewell (Contributor) "IN 1894, many Americans were deeply concerned about labor violence, about an economy sliding into the worst depression the country had ever experienced, and about..." (more)
Key Phrases: vaccine innovation, vaccine operations, vaccine business, New York, United States, New Englandjournal of Medicine (more...)

Editorial Reviews

Review
"...this is a most impressive work....superb at showing the requisites for successful vaccine innovation. It provides outside observers rare insight into decision making processes at a leading pharmaceutical firm." Marvin Fischbaum, H-Net Reviews

"Galambos and Sewell's well-documented book is a valuable and unusual contribution to the history of specialized pharmaceutical endeavor in America, with emphasis on the networking required on the long road leading to each new vaccine." Glenn Sonnedecker, American Historical Review

"...best described by its subtitile because of the narrow focus on the chronological history of Merck's vaccine unit." Book Reviews

"It is beautifully written." Journal of Interdisciplinary History

"Rigorously researched and crisply written, Networks of Innovation....makes a strong case for science-based firms' building and sustaining organizational capabilities to achieve technological innovation as well as to accomodate shifting competitive and regulatory environments." David B. Sicilia, The Journal of American History

"Networks of Innovation deserves a careful and thoughtful reading by historians of technology because it shows how it is possible to analyze effectively the role of individuals in the process of technological change without losing the insights and rigor that come from sociological and economic theory." W. Bernard Carlson, Technology and Culture

Product Description
Networks of Innovation offers a historical perspective on the manner in which private sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp & Dohme, which acquired Mulford in 1929, and on Merck & Co., Inc., which merged with Sharp & Dohme in 1953. By surveying a century of innovation in biologicals, the authors show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad.

See all Editorial Reviews

Product Details

• Hardcover: 320 pages
• Publisher: Cambridge University Press (January 26, 1996)
• Language: English
• ISBN-10: 0521563089
• ISBN-13: 978-0521563086
• Product Dimensions: 9.2 x 6.2 x 0.8 inches
• Shipping Weight: 1.1 pounds
• Average Customer Review: 5.0 out of 5 stars See all reviews (1 customer review)
• Amazon.com Sales Rank: #1,842,375 in Books (See Bestsellers in Books)

  Popular in this category: (What's this?)

  #33 in

  Books > Professional & Technical > Medical > Pharmacology > Research

Customer Reviews

Most Helpful Customer Reviews

5.0 out of 5 stars Knowledge is key, January 18, 2009

By	Angela K. Hall "healthy mom" (fort worth,tx) - See all my reviews (REAL NAME)

This review is from: Networks of Innovation: Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995 (Paperback)

This book does a good job of explaining how the Big-Pharma companies came about. I bought this book for resarch into the unnessary use of vaccinations.